The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study

Yang, Wenchang; Liu, Qian; Lin, Guole; Zhang, Bo; Cao, Hui; Zhao, Yan; Xia, Ling; Feng, Fan; Xiong, Zhiguo; Hu, Junbo; Ye, Yingjiang; Tao, Kaixiong; Zhang, Peng

doi:10.1002/jso.26628

Cited by 8 publications

(10 citation statements)

References 24 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But the information of resection margin was not available in their study. In the contrary, a recent multicenter research ( Yang et al, 2021 ) including 340 cases of rectal GISTs from 11 centers in China reported that, the 3-year rates of DFS and OS of those who received neoadjuvant therapy were 95% and 100%, respectively, which were similar in comparison with those of patients who received no-neoadjuvant therapy. Future updated follow-up is warranted for this multicenter study.…”

Section: Discussionmentioning

confidence: 90%

“…As shown in Figure 1 , 494 relevant publications were identified through the literature search. After screening and assessment, seven eligible studies ( Hawkins et al, 2017 ; Yan et al, 2018 ; NS et al, 2020 ; Yang et al, 2020 ; Ling et al, 2021b ; Marqueen et al, 2021 ; Yang et al, 2021 ) with 17,171 patients were included in this meta-analysis ( Table 1 and Supplementary Table S1 ). There were 1178 patients who received neoadjuvant therapy, and 15,993 patients who received upfront surgery.…”

Section: Resultsmentioning

confidence: 99%

“…What is more, the disease control rate achieved 100% in Ling’s study ( Ling et al, 2021b ). Yang et al ( Yang et al, 2021 ) further reported that the effect of neoadjuvant imatinib is dependent on the genetic type and KIT exon 11 mutation responds better than other types which suggested the importance of genetic sequencing. In the rectal GIST subgroup of current study, a trend of higher R0 resection rate ranging from 85.3% to 98.8% was observed in neoadjuvant imatinib group compared with that ranging from 74.4% to 92.0% in no-neoadjuvant therapy group, though the difference was not significant.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Significant survival benefit of adjuvant imatinib therapy has been observed in gastrointestinal stromal tumor (GIST). However, the impact of neoadjuvant imatinib on prognosis of GIST remains unclear. This meta-analysis aimed to compare the prognostic impact between upfront surgery and neoadjuvant imatinib plus surgery on GIST.Methods: A comprehensive literature search was performed to identify eligible studies up to 30 Sep 2021, through PubMed, Embase, Web of Science, and Cochrane Library. Studies compared the impact of upfront surgery and neoadjuvant imatinib plus surgery on disease-free (DFS) or overall survival (OS) in patients with GIST were selected.Results: Seven eligible studies with 17,171 patients were included. The reduction rates of tumor size in rectal and mixed site GIST were 33% and 29.8%, respectively. Neoadjuvant imatinib was not significantly associated with DFS compared with no-neoadjuvant therapy in rectal GIST (HR: 0.71, 95% CI: 0.35–1.41). The OS of rectal GIST was significantly improved by neoadjuvant imatinib compared with no-neoadjuvant therapy (HR: 0.36, 95% CI: 0.17–0.75).Conclusion: Neoadjuvant imatinib therapy contributed to tumor shrinkage and R0 resection of rectal GIST. Neoadjuvant imatinib plus surgery significantly improved overall survival of rectal GIST in comparison with upfront surgery.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…A study from China comparing neoadjuvant imatinib with upfront surgery also showed favourable outcomes (5-year distant RFS at 97.8 per cent, 5-year disease-specific survival at 100 per cent) in the neoadjuvant group 20 . Another multicentre study from China demonstrated 3-year RFS at 95 per cent with patients receiving neoadjuvant imatinib 21 . This study demonstrated similar results to those reported elsewhere in Asia; however, the five patients who did not receive imatinib were at low risk clinically and pathologically, but one of them developed local recurrence.…”

Section: Discussionmentioning

confidence: 97%

Clinical outcomes of surgical and imatinib treatment for rectal gastrointestinal stromal tumours: retrospective cohort study

et al. 2022

View full text Add to dashboard Cite

Background Rectal gastrointestinal stromal tumours (GISTs) are rare and treated mainly by radical surgery. Although the importance of perioperative imatinib has been recognized, there are few reports on its outcomes. Method Consecutive patients diagnosed with rectal GISTs between July 2008 and February 2021 were identified from a prospective database. Effects of perioperative imatinib were investigated, and surgical and survival outcomes were compared between neoadjuvant imatinib and upfront surgery. Results 34 patients meeting the inclusion criteria were identified. Compared with upfront surgery (n = 11), the neoadjuvant imatinib group (n = 23) had significantly larger tumours (median size 8.3 versus 2.5 cm; P = 0.01) and included a significantly greater proportion of high-risk patients according to the modified Fletcher classification (20/23 (87.0%) versus 6/11 (54.5%); P = 0.02). Comparing the operation planned based on imaging before neoadjuvant imatinib and the operation performed, there was an increase in sphincter-preserving surgery (4/23 (17.4%) to 11/23 (47.8%); P = 0.02), abdominoperineal resection 11/23 (47.8%) reduced to 7/23 (30.4%); P = 0.13) and total pelvic exenteration reduced from 8/23 (34.8%) to 5/23 (21.7%); P = 0.01). Tumours were downsized by a median of 30 per cent (range 0 per cent to −56 per cent; P = 0.01). During follow-up (median 42, range 5–131 months), there was no postoperative recurrence in 29 patients who received perioperative imatinib. One of the five patients who underwent surgery without neoadjuvant or adjuvant imatinib developed local recurrence. Conclusion Treatment with imatinib for rectal GISTs seems to improve outcomes, and neoadjuvant imatinib increases the rate of sphincter-preserving surgery.

show abstract

“… 59 Based on these data, sunitinib was approved by US FDA as a second-line treatment for advanced GIST. 60 …”

Section: Treatment Of Rectal Gistsmentioning

confidence: 99%

Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib

Qu¹,

Xu²,

Ren³

et al. 2022

CMAR

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor of the gastrointestinal tract, with an annual incidence of 10–15 cases per million. However, rectal GIST has a low incidence, accounting for approximately 0.1% of all rectal tumors. The treatment of rectal GISTs is still controversial and the relative unified guidelines and consensus opinions are inadequate. Treatment is based primarily on the clinical experience of the physician. The widespread application of neoadjuvant imatinib therapy allows diversification of treatment, especially in the choice of surgical methods. Herein, we reviewed the most recent literature and summarized the new progress in rectal tumor treatment, with the aim of providing patients with more systematic and individualized therapeutic strategies.

show abstract

The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study

Cited by 8 publications

References 24 publications

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis

Clinical outcomes of surgical and imatinib treatment for rectal gastrointestinal stromal tumours: retrospective cohort study

Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib

Contact Info

Product

Resources

About